| Indication (Target) | Target Organ | Compound | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| Alport syndrome (miR-21) Orphan Disease |
Kidney | RG-012 | Partner: Sanofi Genzyme | |||
| ADPKD (miR-17) | Kidney | RGLS4326 | ||||
| Cholestatic Diseases (Undisclosed Targets) |
Liver | |||||
| HCV backups (miR122) | Liver | |||||
| NASH (undisclosed targets) |
Liver | |||||
| Glioblastoma Multiforme (miR-10b) | CNS | |||||
| Indication (Target) | Target Organ / Compound | Phase |
|---|---|---|
| Alport syndrome (miR-21) Orphan Disease |
Kidney / RG-012 |
Ph2 Partner: Sanofi Genzyme |
| ADPKD (miR-17) | Kidney / RGLS4326 | PreClin |
| Cholestatic Diseases (Undisclosed Targets) |
Liver | PreClin |
| HCV backups (miR122) | Liver | PreClin |
| NASH (undisclosed targets) |
Liver | PreClin |
| Glioblastoma Multiforme (miR-10b) | CNS | PreClin |